Shares of Genelux Corp. (GNLX) have lost over 70% from their 52-week high of $12.12, recorded last January, and trade around $3.15.
This late clinical-stage biopharmaceutical company is developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumors. Its lead drug candidate is Olvi-Vec, a modified form of the oncolytic vaccinia virus.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.